poisar

Stocks · News reference

MiNK Therapeutics Says First Patients In Randomized Phase 2 C-1300-02 Trial Of agenT-797 Alive At Day 28 With Improved Oxygenation, ARDS Resolution, Vasopressor Liberation

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

INKT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Insights

    MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript

    MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to

    INKT